BIOMAT Database Logo BIOMAT Database Logo

[The prostacyclin-thromboxane system and the functional properties of the thrombocytes in patients of different ages with ischemic heart disease]. 1990

I I Ermakovich, and A I Ladnyĭ, and V I Volkov, and V I Tseluĭko

A study is presented of the reactions of prostacyclin-thromboxane system and functions of thrombocytes to physical loads inducing myocardial ischemia in patients with ischemic heart disease of different age groups. Examined were 62 patients with stable stenocardia of the II and III functional classes. Age of the patients: from 44 to 60 years. It was found that the elderly showed deterioration of the prostacyclin-thromboxane imbalance and a reduction of the sensitivity of thrombocytes to prostacyclin. The should be considered in instituting prolonged drug treatment.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D005080 Exercise Test Controlled physical activity which is performed in order to allow assessment of physiological functions, particularly cardiovascular and pulmonary, but also aerobic capacity. Maximal (most intense) exercise is usually required but submaximal exercise is also used. Arm Ergometry Test,Bicycle Ergometry Test,Cardiopulmonary Exercise Testing,Exercise Testing,Step Test,Stress Test,Treadmill Test,Cardiopulmonary Exercise Test,EuroFit Tests,Eurofit Test Battery,European Fitness Testing Battery,Fitness Testing,Physical Fitness Testing,Arm Ergometry Tests,Bicycle Ergometry Tests,Cardiopulmonary Exercise Tests,Ergometry Test, Arm,Ergometry Test, Bicycle,Ergometry Tests, Arm,Ergometry Tests, Bicycle,EuroFit Test,Eurofit Test Batteries,Exercise Test, Cardiopulmonary,Exercise Testing, Cardiopulmonary,Exercise Tests,Exercise Tests, Cardiopulmonary,Fitness Testing, Physical,Fitness Testings,Step Tests,Stress Tests,Test Battery, Eurofit,Test, Arm Ergometry,Test, Bicycle Ergometry,Test, Cardiopulmonary Exercise,Test, EuroFit,Test, Exercise,Test, Step,Test, Stress,Test, Treadmill,Testing, Cardiopulmonary Exercise,Testing, Exercise,Testing, Fitness,Testing, Physical Fitness,Tests, Arm Ergometry,Tests, Bicycle Ergometry,Tests, Cardiopulmonary Exercise,Tests, EuroFit,Tests, Exercise,Tests, Step,Tests, Stress,Tests, Treadmill,Treadmill Tests
D005082 Physical Exertion Expenditure of energy during PHYSICAL ACTIVITY. Intensity of exertion may be measured by rate of OXYGEN CONSUMPTION; HEAT produced, or HEART RATE. Perceived exertion, a psychological measure of exertion, is included. Physical Effort,Effort, Physical,Efforts, Physical,Exertion, Physical,Exertions, Physical,Physical Efforts,Physical Exertions
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging

Related Publications

I I Ermakovich, and A I Ladnyĭ, and V I Volkov, and V I Tseluĭko
[The prostacyclin-thromboxane A2 system in ischemic heart disease].
January 1987, Sovetskaia meditsina,
I I Ermakovich, and A I Ladnyĭ, and V I Volkov, and V I Tseluĭko
[Properties of thrombocytes in patients with ischemic heart disease].
April 1987, Vrachebnoe delo,
I I Ermakovich, and A I Ladnyĭ, and V I Volkov, and V I Tseluĭko
[Structural and functional properties of the thrombocytes in ischemic heart disease].
January 1984, Biulleten' eksperimental'noi biologii i meditsiny,
I I Ermakovich, and A I Ladnyĭ, and V I Volkov, and V I Tseluĭko
[The prostacyclin-thromboxane system and thrombocytic-vascular hemostasis in patients with ischemic heart disease in the preoperative period].
January 1992, Anesteziologiia i reanimatologiia,
I I Ermakovich, and A I Ladnyĭ, and V I Volkov, and V I Tseluĭko
[Status of the prostacyclin-thromboxane A2 system in patients with ischemic heart disease during induced myocardial ischemia].
January 1988, Sovetskaia meditsina,
I I Ermakovich, and A I Ladnyĭ, and V I Volkov, and V I Tseluĭko
[Prostacyclin-thromboxane system in children and adolescents with a high risk of developing ischemic heart disease].
January 1992, Voprosy meditsinskoi khimii,
I I Ermakovich, and A I Ladnyĭ, and V I Volkov, and V I Tseluĭko
[Prostacyclin-thromboxane balance and risk factors of ischemic heart disease].
September 1989, Kardiologiia,
I I Ermakovich, and A I Ladnyĭ, and V I Volkov, and V I Tseluĭko
[Functional status of thrombocytes in patients with acute forms of ischemic heart disease].
January 1987, Klinicheskaia meditsina,
I I Ermakovich, and A I Ladnyĭ, and V I Volkov, and V I Tseluĭko
Reduced prostacyclin production in patients with different manifestations of ischemic heart disease.
April 1982, The American journal of cardiology,
I I Ermakovich, and A I Ladnyĭ, and V I Volkov, and V I Tseluĭko
[Survival of the thrombocytes in patients with ischemic heart disease].
October 1973, Kardiologiia,
Copied contents to your clipboard!